Q
Quell Therapeutics
Engineered T-regulatory cell therapies for immune-driven diseases
At a glance
- Founded
- 2019
- Headquarters
- London, United Kingdom
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- ALAlbionVC
- UFUCL Technology Fund
- SYSyncona
Series B and later14 investors entered at this stage
- MMMonashee Investment Management
- MHMedizinische Hochschule Hannover
- RCRidgeback Capital
- KLKing's College London
- BCBritish Patient Capital
Janus Henderson Investors- BVBreakthrough Energy Ventures
- ULUniversity College London
- FFFuture Fund
- JCJeito Capital
Fidelity Investments- SISV Health Investors
- TMTekla Capital Management
- PVPoint72 Ventures
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quell Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.